Lianbio (LIAN)

$1.5

Market is closed - opens 7 PM, 25 Sep 2023

Insights on Lianbio

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 288.9% return, outperforming this stock by 315.4%

Performance

  • $1.47
    $1.62
    $1.50
    downward going graph

    2.0%

    Downside

    Day's Volatility :9.03%

    Upside

    7.17%

    downward going graph
  • $1.07
    $2.90
    $1.50
    downward going graph

    28.67%

    Downside

    52 Weeks Volatility :63.1%

    Upside

    48.28%

    downward going graph

Returns

PeriodLianbioSector (Health Care)Index (Russel 2000)
3 Months
-37.76%
-1.4%
0.0%
6 Months
-11.76%
2.2%
2.0%
1 Year
-26.47%
6.0%
5.3%
3 Years
-89.05%
28.4%
21.8%

Highlights

Market Capitalization
195.0M
Book Value
$2.07
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.82
Wall Street Target Price
7.74
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-20.14%
Return On Equity TTM
-29.51%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-103.6M
Diluted Eps TTM
-0.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.04
EPS Estimate Next Year
-1.2
EPS Estimate Current Quarter
-0.28
EPS Estimate Next Quarter
-0.32

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Lianbio(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 416.0%

Current $1.50
Target $7.74

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lianbio
Lianbio
-18.92%
-11.76%
-26.47%
-89.05%
-89.05%
Moderna, Inc.
Moderna, Inc.
-13.4%
-33.08%
-16.46%
53.43%
437.58%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.9%
2.83%
20.22%
47.96%
111.39%
Novo Nordisk A/s
Novo Nordisk A/s
2.74%
149.34%
288.91%
457.87%
693.95%
Seagen, Inc.
Seagen, Inc.
9.23%
7.87%
53.52%
19.21%
172.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.31%
14.69%
26.28%
32.84%
91.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lianbio
Lianbio
NA
NA
NA
-1.04
-0.3
-0.2
0.0
2.07
Moderna, Inc.
Moderna, Inc.
34.92
34.92
0.0
-3.42
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.9
21.9
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
42.86
42.86
2.03
1.66
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.48
27.48
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lianbio
Lianbio
Buy
$195.0M
-89.05%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.1B
437.58%
34.92
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$89.4B
111.39%
21.9
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$409.3B
693.95%
42.86
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.7B
172.13%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.2B
91.87%
27.48
35.4%

Institutional Holdings

  • Perceptive Advisors LLC

    53.71%
  • Cormorant Asset Management, LLC

    3.97%
  • Viking Global Investors LP

    3.33%
  • Tybourne Capital Management (HK) Ltd

    3.08%
  • T. Rowe Price Associates, Inc.

    2.53%
  • Vida Ventures Advisors, LLC

    2.13%

Corporate Announcements

  • Lianbio Earnings

    Lianbio’s price-to-earnings ratio stands at None

    Read More

Company Information

lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.

Organization
Lianbio
Employees
163
CEO
Mr. Konstantin Poukalov
Industry
Healthcare

FAQs